Caricamento azienda
Just reported
From Crispr Therapeutics's results release of 2 novembre 2026; its quarterly report has since been filed.
Actual
12,7M USD
+24% q/q
Guided
—
No guide given
Actual
-1,15 USD
Guided
—
No guide given
Actual
-130M USD
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
The themes Crispr Therapeutics is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
ONCBeone Medicines Ltd.47,5B USDA+
EXELExelixis, Inc.17B USDA+
JAZZJazz Pharmaceuticals plc15,4B USDA
HALOHalozyme Therapeutics, Inc.11,5B USDA+
TECHBIO-Techne Corp11,4B USDA+Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21 ott 2026CBGraded C, now B
MCKMckesson Corporation4 nov 2026BAGraded B, now A
CVSCVS Health Corp4 nov 2026BAGraded B, now A
EWEdwards Lifesciences Corporation4 nov 2026BAGraded B, now A
BIIBBiogen Inc.28 ott 2026BAGraded B, now ACostruito dai documenti depositati da Crispr Therapeutics AG presso la Securities and Exchange Commission (SEC), l’autorità di vigilanza statunitense. Le cifre sono quelle dichiarate, con lo storico per azione ricalcolato sulla base azionaria di oggi. Questo descrive un’azienda: non è consulenza finanziaria né una raccomandazione di acquisto o vendita.
Grade F-
La fascia sotto il prezzo mostra il voto in ogni data, calcolato solo sui documenti già pubblici in quel momento.
Mostra 2 trimestri su 40 dello storico dei voti di Crispr Therapeutics AG. Gli altri 38 risalgono fino a marzo 2017.
